Result of benign prostatic hyperplasia treatment in rural hospital under Intra-provincial medicine fund with IT application based

Abstract

Source: Benign prostatic hyperplasia is one of the most common long-term, non-communicable diseases in the outpatient environment (BPH). A general practitioner, internist, or urologist can currently treat BPH. But nowadays mostly of BPH patients were referred to Urologist due to problem of drug management system. On the other hand, Urologists are only available in regional center hospitals. However, because there are numerous patients, the patients need to go to the provincial hospital with great distances and require a long waiting time. Consequently, a system of Intra-provincial medicine funds was established. We created an application to send patient data to the rural hospital for treatment by General practice, enabling patients to obtain standard care. Obtain complete patient data while lowering costs and travel time to the hospital. Result: There was no statistically significant difference (p-value < 0.05) in the quality of patient treatment using IPSS and treatment side effects. Nevertheless, the patients' cost and travel time to the rural hospital were significantly less than the Chiang Rai Prachanukroh hospital. In terms of program integrity, no lack of referral information incidence was reported. Furthermore, it can send complete disbursement information to withdraw from the government. Conclusion: The quality of treatment of patients with Benign prostatic hyperplasia treated with medication by a general practitioner at a rural hospital under the Intra-provincial medicine fund is similar to that of a urologist at Chiang Rai Prachanukroh hospital. Reduce costs and travel time for the provincial hospital and use an application to forward patient information for treatment and disbursement information. Able to forward complete information and no problem with disbursement.

References

Bernadino  M., Antonio H.,  Enrique O., et al. CANPRIMARY CARE PHYSICIANS MANAGE BENIGNPROSTATIC HYPERPLASIA PATIENTS AS UROLOGISTSDO?. European Medical Journal. July 2014; 1-8.

Cam, K., Senel, F., Akman, Y., & Erol, A. The efficacyof an abbreviated model of the International ProstateSymptom Score in evaluating benign prostatic hyperplasia. BJU International 2003; 91(3), 186–9.

Eric H. Kim, Jeffrey A. Larson, and Gerald L. AndrioleManagement  of  Benign  Prostatic  Hyperplasia.  Annu.Rev. Med. 2016. 67:137–51.

LERNER, Lori B., et al. Management of Lower Urinar TractSymptoms Attributed to benign prostatic hyperplasia: AUAGUIDELINE  PART  I—initial  work-up  and  medicalmanagement. The Journal of urology, 2021, 206.4: 806-817.

LERNER, Lori B., et al. Management of lower urinartract symptoms attributed to benign prostatic hyperplasia:AUA guideline part II—surgical evaluation and treatment. The Journal of urology, 2021, 206.4: 818-826.

Raman  U.,  Nima  A.,  Khaled  F.  The  efficacy  of  anabbreviated model of the International Prostate SymptomScore in evaluating benign prostatic hyperplasia. BJUInternational,  Cleveland  clinical  journal  of  medicine.Vol. 84 2017; 53-64.

Ruud Bosch, J. L. H., Hop, W. C. J., Kirkels, W. J.,Schröder,  F.  H.  Natural  history  of  benign  prostatichyperplasia: Appropriate case definition and estimation of  its  prevalence  in  the  community.  Urology.  1995. 46(3):34–40.

1. Gravas (Chair), J.N. Cornu, M. Gacci, et al. Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS),incl. Benign Prostatic Obstruction  (BPO). European Association of Urology 2022.

Zoran Kričković, Milan Simatović, Darko Lukić, Andrea Stanojević, Velimir Škrbić, Goran Janjić. Frequency of Common Complications During Treatment of Patients with Benign Prostate Hyperplasia. Scr Med 2020; 51(1):48-53.

งานเวชระเบียนโรงพยาบาลเชียงรายประชานุเคราะห์. ข้อมูล  และสถิติผู้ป่วยนอกแผนกศัลยกรรมระบบทางเดินปัสสาวะ โรงพยาบาลเชียงรายประชานุเคราะห์ ปีงบประมาณ 2564-65. เชียงราย: โรงพยาบาล; 2565